Fresh Promise In The Aids FightBy
Investment pro Jack Rivkin, senior vice-president of Travelers Group, parent of Travelers Insurance and Smith Barney, is used to making bets on health-care stocks. His most recent venture has led him to a little-known company: Paracelsian (PRLN), a biotech outfit engaged in developing drugs from herbal sources and designing tests for improved cancer diagnosis.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.